Abstract 364P
Background
To develop artificial intelligence auto-segmentation model that generates consistent, high-quality lymph nodes contouring in head and neck cancer patients who received radiotherapy.
Methods
There were 60 computed tomography (CT) scans were retrospectively selected into training and another 60 CT scans were collected into cross-validation. All target delineations covered head and neck lymph node level I through V and based on the Radiation Therapy Oncology Group (RTOG) guideline. All targets were approved by radiation oncologists specializing in head and neck cancer. The volume of interest and all approved contours were used to train a 3D U-Net model. Different lymph node levels were trained independently. The trained model was used on cross-validation group. Auto-segmentations were revised by 2 radiation oncologists.
Results
The Dice Similarity Coefficients were 0.79 and 0.88 in trained group and cross-validation group. The volume changes ranged from -22.2 to 89.0 cm3. The center shift for x-direction, y-direction, and z-direction were -0.57 to 0.16 cm, -0.14 to 0.88 cm, and -0.19 to 0.38 cm, respectively.
Conclusions
We developed an artificial intelligence auto-segmentation model to autodelineate head and neck lymph nodes. Most results of auto-segmentations were acceptable after radiation oncologist review. This enables more efficient and consistent targeting of neck lymph nodes in radiation treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China
Presenter: Hanxiao Chen
Session: Poster Display
Resources:
Abstract
593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)
Presenter: E-e Ke
Session: Poster Display
Resources:
Abstract
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Presenter: Koichi Goto
Session: Poster Display
Resources:
Abstract
596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
Presenter: Ross Soo
Session: Poster Display
Resources:
Abstract
597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC
Presenter: Sun Min Lim
Session: Poster Display
Resources:
Abstract
598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)
Presenter: Haiyi Deng
Session: Poster Display
Resources:
Abstract
599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)
Presenter: Shuting Zhan
Session: Poster Display
Resources:
Abstract
600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)
Presenter: Junko Tanizaki
Session: Poster Display
Resources:
Abstract
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract